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Objectives The aim of this study was to study whether there is a difference in beneﬁt of fractional
ﬂow reserve (FFR) guidance for percutaneous coronary intervention (PCI) in multivessel coronary dis-
ease in patients with unstable angina (UA) or non–ST-segment elevation myocardial infarction
(NSTEMI), compared with stable angina (SA).
Background The use of FFR to guide PCI has been well established for patients with SA. Its use in
patients with UA or NSTEMI has not been investigated prospectively.
Methods In the FAME (Fractional ﬂow reserve versus Angiography for Multivessel Evaluation) study
1,005 patients with multivessel disease amenable to PCI were included and randomized to either
angiography-guided PCI of all lesions 50% or FFR-guided PCI of lesions with an FFR 0.80. Pa-
tients admitted for UA or NSTEMI with positive troponin but total creatine kinase 1,000 U/l were
eligible for inclusion. We determined 2-year major adverse cardiac event rates of these patients and
compared it with stable patients.
Results Of 1,005 patients, 328 had UA or NSTEMI. There was no evidence for heterogeneity among
the subgroups for any of the outcome variables (all p values 0.05). Using FFR to guide PCI re-
sulted in similar risk reductions of major adverse cardiac events and its components in patients with
UA or NSTEMI, compared with patients with SA (absolute risk reduction of 5.1% vs. 3.7%, respec-
tively, p  0.92). In patients with UA or NSTEMI, the number of stents was reduced without increase
in hospital stay or procedure time and with less contrast use, in similarity to stable patients.
Conclusions The beneﬁt of using FFR to guide PCI in multivessel disease does not differ between
patients with UA or NSTEMI, compared with patients with SA. (J Am Coll Cardiol Intv 2011;4:
1183–9) © 2011 by the American College of Cardiology Foundation
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FFR in UA and NSTEMI
1184The use of fractional flow reserve (FFR) to select coronary
stenoses associated with reversible ischemia and that will
benefit most by stenting has been well established in
patients undergoing elective percutaneous coronary inter-
vention (PCI) (1–3). Its use in unstable angina (UA) and
non–ST-segment elevation myocardial infarction (NSTEMI) is
less well investigated.
Several retrospective and a few small prospective studies
have indicated that in such patients FFR can be used in a
similar way as in stable angina pectoris (SA), but no large
randomized study has been performed so far (4–7). Espe-
cially in multivessel disease when several stenoses are pres-
ent, selection of the culprit lesion in case of UA or
NSTEMI might be difficult. Often electrocardiography is
helpful and indicates the lesion responsible for the acute
ischemia, but sometimes it does not. In addition, even when
the culprit lesion is known, doubt might arise about the
ischemic potential of other con-
comitant lesions and the necessity
to treat such lesions invasively.
In the recently published pro-
spective and randomized FAME
(Fractional flow reserve versus
Angiography for Multivessel
Evaluation) study, FFR-guided
PCI in multivessel disease was
compared with angiography-
guided PCI in 1,005 patients.
The FAME study demon-
strated the superiority of FFR-
guided PCI over angiography
guidance alone in patients with
multivessel disease, with a de-
crease of all types of events by
approximately 30% up to 2 years
of follow-up without prolongation
of the procedure, at lower costs
and with less use of contrast agent, a shorter hospital stay, and
an at least equal functional class at 1- and 2-year follow-up
(3,8,9).
In the FAME study, 328 patients were included who
were admitted because of UA or NSTEMI. The outcome of
FFR-guided PCI versus angiography-guided PCI in these
patients and comparison with the 677 patients with SA is
the subject of this study.
Methods
The FAME study design and patient population. The FAME
study is a multicenter prospective trial in 1,005 patients with
multivessel coronary artery disease undergoing PCI by
stenting with drug-eluting stents. Patients were randomly
assigned to either angiography-guided PCI or FFR guid-
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
FFR  fractional flow
reserve
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
SA  stable angina
STEMI  ST-segment
elevation myocardial
infarction
UA  unstable anginaance in addition to angiography. The decision and selectionof those coronary stenoses that required stenting was based
upon visual estimation on the angiogram (angiography-
guided group) or upon FFR measurements (FFR-guided
group), in addition to clinical data.
Patients assigned to angiography-guided PCI underwent
stenting of all stenoses 50% by visual estimation of which
he operator deemed stenting indicated. In patients assigned
o the FFR-guided PCI, FFR was measured first in all such
esions, and stenting was only performed if FFR was0.80.
Exclusion criteria were left main disease, previous
ABG, and ST-segment elevation myocardial infarction
STEMI) 5 days before, because the use of FFR is not
alidated in recent STEMI (10). However, patients admit-
ed for UA (whether or not with transient ST-segment
hanges) and NSTEMI with positive troponin but total
reatine kinase 1,000 U/l could be included.
Of the 1,005 patients, 328 (32%) had an initial diagnosis
f UA or NSTEMI. Strict criteria were used to distinguish
etween NSTEMI and periprocedural infarction as previ-
usly described (11). Further details about the FAME trial
ave been extensively described elsewhere (11).
FFR. Fractional flow reserve is an index of the physiological
ignificance of a coronary stenosis and is defined as the ratio of
aximal blood flow in a stenotic artery to normal maximal
ow. It can be easily measured during coronary angiography by
alculating the ratio of distal coronary pressure measured with
coronary pressure guidewire to aortic pressure measured
imultaneously with the guiding catheter during maximum
yperemia (12). The FFR in a normal coronary artery equals
.0. An FFR value of 0.80 or less identifies ischemia-causing
oronary stenoses with an accuracy of more than 90% (13). The
nformation provided by FFR is similar to that obtained with
yocardial perfusion studies, but FFR is more specific and has
better spatial resolution, because every artery or segment is
nalyzed separately and masking of 1 ischemic area by another
ore-severely ischemic area is avoided (14,15).
Treatment. The interventional treatment of patients in the
AME study has been described previously and was iden-
ical for patients with SA and for patients admitted because
f UA or NSTEMI (11). Percutaneous coronary interven-
ion was performed with standard techniques and with
rug-eluting stents. The FFR was measured with a coronary
ressure guidewire (St. Jude Medical Systems, Uppsala,
weden) at maximum hyperemia induced by intravenous
denosine, administered at a rate of 140 g/kg/min through
central vein. Pressure pullback recordings were performed
n all indicated arteries. All patients were treated with
spirin and clopidogrel for at least 1 year after PCI. Use of
eriprocedural glycoprotein IIb/IIIa antagonists was at the
iscretion of the operator.
Endpoints and follow-up. The subject of this study was the
occurrence of major adverse cardiac events (MACE) and their
individual components at 2 years. Major adverse cardiac events
were defined as composite of death from any cause, myocardial
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1185infarction (MI), and any repeat revascularization. Details on
these definitions have been described previously (3,11).
Also, functional class at 2 years was assessed.
Statistical analysis. Data management and statistical analy-
sis were performed by an independent data coordinating
center (UMIT–University for Health Sciences, Hall in
Tirol, Austria).
An independent clinical events committee whose mem-
bers were unaware of the treatment assignments adjudicated
all events. All enrolled patients were included in the analysis
of MACE according to the intention-to-treat principle.
To test for heterogeneity for the effect of using FFR in
the strata of UA or NSTEMI and SA, Breslow-Day testing
was performed—a 2-sided p value 0.05 signifying hetero-
geneity. For descriptive purposes, we compared the effect of
FFR-guided therapy versus angiography-guided therapy
within subgroups.
Categorical variables, including the primary endpoint and its
individual components, are expressed as proportions and were
compared with chi-square test. Continuous variables are ex-
pressed as mean  SD and were compared with an unpaired
t test or the Mann-Whitney U test as appropriate. A 2-sided
p value of 0.05 was considered to indicate statistical signifi-
ance. Kaplan-Meier curves are shown for the time-to-event
istributions of MACE in all patients stratified according to
iagnosis (UA or NSTEMI or SA) and treatment strategy
angiography- or FFR-guided PCI).
All statistical analyses were performed with SAS software
version 9, SAS Institute, Cary, North Carolina).
esults
Baseline characteristics. Of 1,005 patients enrolled in the
AME study, 328 patients (32%) had UA or NSTEMI, of
hich 178 were randomized to angiography-guided PCI
nd 150 were randomized to FFR-guided PCI.
The baseline characteristics of the patients with UA or
STEMI and patients with SA are mentioned in Table 1.
lthough most baseline characteristics were equally distrib-
ted, patients with UA or NSTEMI in comparison with SA
ere less likely to be male (69% vs. 77%, p  0.01), more
ften had previous MI (44% vs. 33%; p  0.01), more often
sed beta blockade (81% vs. 75%, p  0.017) and clopi-
ogrel (70% vs. 40%, p  0.01), less often used statins (77%
s. 83%, p  0.02), and had a higher Euro-score (2.8  2.2
vs. 3.2  2.3, p  0.01). The angiographic severity of
disease (number and severity of lesions and Syntax score)
and FFR measurements, however, were not different be-
tween patients with UA or NSTEMI and patients with SA.
Next, patients were categorized according to diagnosis
(UA or NSTEMI or SA) and treatment strategy
(angiography-guided PCI or FFR-guided PCI), thus ren-
dering 4 groups.Baseline characteristics of these 4 groups are presented in
Table 2.
Procedural results. UA OR NSTEMI VERSUS SA. There was no
difference between patients with UA or NSTEMI and
patients with SA with respect to the number of indicated
lesions/patient (2.7  0.9 vs. 2.8  1.0, p  0.06), the
percentage of hemodynamically significant lesions within
the FFR-guided groups (61.8% vs. 63.5%, p  0.54), or the
percentage of successfully treated lesions (97.5% vs. 96.9%,
p  0.42).
There was no significant difference in procedure time,
contrast use, number or type of stents used, or use of
glycoprotein IIb/IIIa inhibitors. Hospital stay was signifi-
cantly longer for patients with UA or NSTEMI than for
patients with SA (4.5  4.5 days vs. 3.1  2.7 days, p 
.01). These data are shown in Table 1.
FFR-GUIDANCE VERSUS ANGIOGRAPHY-GUIDANCE IN UA OR
NSTEMI. In the patients with UA or NSTEMI, procedural
uccess, procedure time, and duration of hospital stay were
ot different between the FFR-guided group and the
ngiography-guided group, except for contrast use, which
as significantly higher in the angiography-guided group
308  134 ml vs. 269  139 ml, p  0.01). In patients
ith UA or NSTEMI assigned to FFR-guidance group, on
verage 1 stent less/patient was used than in those assigned
o angiography guidance (1.9 1.5 vs. 2.9 1.1, p 0.01),
s shown in Table 3.
2-year outcome. BENEFIT OF FFR-GUIDANCE IN UA OR
STEMI COMPARED WITH SA. We found no evidence for
heterogeneity in effect of FFR guidance among the sub-
groups of UA or NSTEMI and SA.
In the patients with UA or NSTEMI, the absolute
reduction of MACE at 2 years by using FFR guidance was
5.1% versus 3.7% in patients with SA. The relative risk
reduction of MACE was 19% versus 18%, respectively. The
rates of MACE and its individual components, absolute and
relative risk reductions by FFR-guidance, and Breslow-Day
test for MACE and its components are shown in Table 4.
Kaplan-Meier curves for survival free from MACE for
the patients in all groups are presented in Figure 1.
UA OR NSTEMI VERSUS SA. The composite of death, MI, and
repeated revascularization at 2 years occurred in 24.1% of all
patients with UA or NSTEMI versus 18.2% of patients with
SA (p  0.03). There was also a significant difference in
occurrence of MI (10.9% vs. 6.5%, p 0.02) and death or MI
(13.7% vs. 9.2%, p 0.04). Functional status at 2 years did not
differ. These data are shown in Table 1.
Discussion
As previously shown in the FAME study (9), using FFR to
guide PCI in multivessel disease resulted in significant
reduction of MI and mortality at 2 years. In this sub-
analysis, we found no evidence for a difference of the effect
ntion; S
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1186of using FFR between patients with UA or NSTEMI and
patients with SA. The guidance of PCI by FFR rather than
angiography alone was associated with similar relative risk
reductions of MACE, death, MI, and death or MI in
patients with UA and NSTEMI and patients with SA.
The reduction of events by FFR-guidance in patients
with UA or NSTEMI is obtained by using fewer stents, as
Table 1. Demography, Clinical Characteristics, Proce
2 Years of Patients With UA or NSTEMI Compared W
Demography
Age, yrs
Male
Clinical characteristics
History of
Previous MI
Previous PCI
Diabetes
Hypertension
Current smoker
Hypercholesterolemia
Positive family history
Left ventricular ejection fraction, %
EuroSCORE
SYNTAX score
Procedural characteristics
No. of indicated lesions/patient
Successfully treated lesions, %
Procedure time, min
Contrast agent used, ml
Drug-eluting stents used/patient, n
Hospital stay at baseline admission, days
GP IIb/IIIa inhibitor
FFR results
Lesions successfully measured by FFR
FFR (all lesions)
FFR 0.80 (ischemic lesions)
FFR 0.80 (nonischemic lesions)
Lesions with FFR 0.80, %
Endpoints
Death, MI, CABG, or repeat PCI
Death
MI
Death or MI
CABG or repeat PCI
Functional status
Functional status at 2 yrs
Patients without event and free from angina
Patients free from angina
Values are mean SD or n (%). *Significant p value (0.05).
CABG coronary artery bypass grafting; FFR fractional flow reserv
elevation myocardial infarction; PCI percutaneous coronary intervein patients with SA.This latter observation can be explained because, also in
UA or NSTEMI in patients with multivessel coronary
disease, unnecessary stenting of nonischemic lesions in-
creases the chance of stent thrombosis, in-stent restenosis,
and periprocedural complications, which—in contrast to
ischemic lesions—is not outweighed by the benefit of
relieving myocardial ischemia (2). Moreover, if the culprit
Data, Outcome, and Functional Status at
tients With SA
or NSTEMI
n  328)
SA
(n  677) p Value
4.8 10.7 64.3 10.0 0.41
226 (69) 518 (77) 0.01*
144 (44) 223 (33) 0.01*
100 (30) 175 (26) 0.13
71 (22) 177 (26) 0.13
212 (65) 427 (63) 0.68
98 (30) 196 (29) 0.77
230 (70) 498 (74) 0.25
142 (43) 253 (37) 0.07
58 11.5 57 11.5 0.16
3.2 2.3 2.8 2.2 0.01*
4.7 8.4 14.4 8.9 0.69
2.7 0.9 2.8 1.0 0.06
96.9 97.4 0.42
70 43 70 44 1.0
90 137 286 128 0.60
.43 1.38 2.4 1.36 0.71
4.5 4.5 3.1 2.7 0.01*
55 (17) 85 (13) 0.08
1/420 (93) 938/994 (94) 0.39
.60 0.13 0.60 0.14 0.65
.87 0.06 0.88 0.05 0.43
61.8 63.5 0.54
79 (24.1) 123 (18.2) 0.03*
12 (3.7) 20 (3.0) 0.44
36 (11) 44 (6.5) 0.02*
45 (13.7) 62 (9.2) 0.04*
45 (13.7) 72 (10.6) 0.17
n 282 n 618
177 (62.8) 422 (68.3) 0.11
209 (74.1) 492 (79.6) 0.07
glycoprotein;MImyocardial infarction; NSTEMInon–ST-segment
A stable angina; UA unstable angina.dural
ith Pa
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1187times the case in UA or NSTEMI, FFR can be helpful to
select it. Importantly, at the same time concomitant lesions
can be interrogated for being responsible for reversible
ischemia, and a better decision can be made as to whether or
not to treat those lesions invasively.
It has been widely advocated that acute coronary syn-
dromes primarily occur in nonsignificant lesions, and some-
times so-called plaque sealing of all lesions in UA or
NSTEMI is advocated on the basis of morphological
characteristics of plaque vulnerability (16–19). However, we
found no evidence that guiding treatment by FFR and thus
only treating ischemia-causing lesions would be less bene-
ficial in UA or NSTEMI than in SA. An important
observation in this respect is that in the patients with UA or
NSTEMI none of the MIs at follow-up in the FFR-guided
group occurred on previously deferred lesions, underlining
the safety of deferring nonsignificant lesions even in unsta-
ble coronary disease (9).
Table 2. Baseline Characteristics of Patients Stratified to Diagnosis and T
UA or NSTEMI
Angiography
(n  178)
FFR
(n  150)
Age, yrs 64.2 10.5 65.6 11.0
Male 116 (65) 110 (73)
History of
Previous MI 78 (44) 66 (44)
Previous PCI 50 (28) 50 (33)
Diabetes 38 (21) 33 (22)
Hypertension 122 (69) 90 (60)
Current smoker 55 (31) 43 (29)
Hypercholesterolemia 129 (72) 101 (67)
Positive family history 73 (41) 69 (46)
LVEF, % 58.5 12.3 57.3 10.4
EuroSCORE 3.3 2.3 3.8 2.5
SYNTAX score 13.9 7.6 15.6 9.1
Values are mean SD or n (%). A p value of0.05 is considered statistically significant.
EuroSCORE European Systems for Cardiac Operative Risk Evaluations; LVEF left ventricular e
Table 3. Angiographic and Procedural Data of Patients Stratified According
UA or NSTEMI
Angiography
(n  178)
FFR
(n  1
No. of indicated lesions/patient 2.6 0.8 2.7
Procedural success rate 97 98.4
Drug-eluting stents used/patient 2.9 1.1 1.9
Procedure time, min† 71 48 69
Contrast agent used, ml 308 134 269
GP IIb/IIIa inhibitor 31 (17) 24 (1
Hospital stay at baseline admission, days 4.6 4.2 4.5
Values are mean SD, %, or n (%). *Significant p value (0.05). †Plus-minus values are means SAbbreviations as in Table 1.The present data also indicate that the 2-year event rate
is higher for patients who present with UA or NSTEMI
than for patients with SA (24.1% vs. 18.2%), stressing the
negative impact of unstable coronary disease on prognosis
and at the same time showing that these patients in the
FAME population are in fact at increased risk of MACE,
compared with stable patients. This is reflected in similar
relative risk reduction but larger absolute risk reduction by
using FFR in these patients.
Study limitations. First of all, the FAME study was pow-
red to show a difference in outcome at 1 year between
ngiography-guided and FFR-guided PCI with an alpha
evel of 0.05 and a statistical power of 0.80, assuming event
ates at 1 year in the complete study population of 14% in
he angiography-guided group and 8% in the FFR-guided
roup. This means that, for analysis of smaller subgroups,
his study in fact is not powered to show superiority of 1
reatment modality above the other. Moreover, the study
ent Strategy
SA
Value
Angiography
(n  318)
FFR
(n  359) p Value
0.22 64.2 10.0 64.3 10.0 0.95
0.12 244 (77) 274 (76) 0.93
1.00 102 (32) 121 (34) 0.68
0.34 79 (25) 96 (27) 0.60
0.89 87 (27) 90 (25) 0.54
0.13 205 (65) 222 (62) 0.52
0.71 101 (32) 95 (26) 0.15
0.33 233 (73) 265 (74) 0.93
0.37 117 (37) 136 (39) 0.81
0.37 56.4 11.9 57.2 11.3 0.39
0.46 2.6 2.1 2.7 2.1 0.71
0.08 14.8 9.4 14.1 8.4 0.28
fraction; other abbreviations as in Table 1.
iagnosis and Treatment Strategy
SA
p Value
Angiography
(n  318)
FFR
(n  359) p Value
0.61 2.8 0.9 2.8 1.0 0.54
0.32 96.4 97.6 0.23
0.01* 2.8 1.2 2.0 1.4 0.01*
0.72 69 41 71 46 0.54
0.01* 299 124 273 130 0.08
0.77 45 (15) 40 (11) 0.24
0.76 3.2 2.9 3.0 2.5 0.42reatm
pto D
50)
1.0
1.5
35
139
6)
4.7
D.
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1188was not powered to detect differences in subgroups, and
therefore, the statistically nonsignificant heterogeneity test
must be interpreted as absence of evidence for different effects
but is not a proof for the equality of effects across subgroups. If,
in studies like this, statistical significance is present in 1 of the
complementary subgroups (UA or NSTEMI and SA), it either
indicates absence of an effect in the other subgroup or over-
powering of the study. Therefore, testing for (or showing
evidence against) heterogeneity is the correct purpose of an
analysis like this. Nevertheless, it is desirable to confirm these
findings of the utility of FFR in patients with UA or NSTEMI
in a separate prospective study.
Table 4. Outcome and Functional Status at 2 Years of Patients Stratified t
UA or NSTEMI
Angiography FFR ARR (%)
Events at 2 yrs n 178 n 150
MACE (death, MI, CABG, or repeat PCI) 47 (26.4) 32 (21.3) 5.1
Death 8 (4.5) 4 (2.7) 1.8
MI 24 (13.5) 12 (8.0) 5.5
Death or MI 30 (16.9) 15 (10.0) 6.9
CABG or repeat PCI 25 (14.0) 20 (13.3) 0.7
All events 57 (32) 36 (24) 8.0
Functional status at 2 yrs n 147 n 135 p value
Patients without event and
free from angina
95 (64.6) 82 (60.7) 0.54
Patients free from angina 110 (74.8) 99 (73.3) 0.78
Values are n (%) or %. Absolute (ARR) and relative risk reductions (RRR) by using FFR for both pati
treatment for the different outcomes are also shown. A p value0.05 is considered statistically sign
nonsignificant. †Breslow-Day indicates Breslow-Day test for heterogeneity of odds ratio of FFR-gui
MACEmajor adverse cardiac events; other abbreviations as in Table 1.
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Figure 1. Kaplan-Meier Curves for Survival Free From MACE at 2 Years Str
Kaplan-Meier curves for the percentage survival free from major adverse cardi
risk reduction (AAR) and relative risk reduction (RRR) of MACE by fractional ﬂo
ble angina (UA) or non–ST-segment elevation myocardial infarction (NSTEMI) and paSecond, the use of FFR in acute coronary syndromes can
be limited by microvascular obstruction, which is often
present with extensive MI, although this is still debated
(20–24). However, in UA or NSTEMI with creatine kinase
1,000 U/l as defined in the FAME study, obviously the
degree of microvascular obstruction—if present—was so
limited or rapidly transient that the usefulness of FFR for
selection of lesions to be treated was not affected.
This is different from extensive STEMI, excluded in the
FAME study, where microvascular obstruction in the in-
farcted area can be extensive and stunning can last for
several days. In such situations, FFR should not be used
gnosis and Treatment Strategy
SA
RR (%) Angiography FFR ARR (%)* RRR (%)
Breslow-Day
p Value†
n 318 n 359
19 64 (20.1) 59 (16.4) 3.7 18 0.922
40 11 (3.5) 9 (2.5) 1.0 29 0.786
41 25 (7.9) 19 (5.3) 2.6 33 0.742
41 34 (10.7) 28 (7.8) 2.9 27 0.556
5 38 (11.9) 34 (9.5) 2.4 20 0.624
25 74 (23.3) 62 (17.3) 6.0 26 0.933
n 291 n 327 p value
189 (64.9) 233 (71.3) 0.10
222 (76.3) 270 (82.6) 0.06
th UA or NSTEMI and patients with SA are shown. Interaction between UA or NSTEMI and SA and
*Differences in endpoints between treatment strata within diagnosis subgroups are all statistically
versus the odds ratio of angiography-guided PCI within each diagnosis subgroup.
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1189until transient microvascular obstruction has resolved and
demarcation between vital and necrotic tissue has occurred.
Previous studies have indicated that, after STEMI, FFR
should not be used to make decisions within the first 5 days
after the acute event, which was an exclusion criterion in the
FAME study (10).
Conclusions
In patients with UA or NSTEMI in the FAME study,
there is no heterogeneity in benefit of FFR guidance of PCI,
compared with patients with SA.
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